Dr. Madi Madiyalakan will be holding an on-floor seminar on the above topic at 5th Annual BioPharma Asia Convention 2012, held on 19th to 22nd March 2012 at Marina Bay Sands, Singapore. He will be speaking at Theatre 3, on the 20th of March 14:00.
Dr. Madiyalakan is the CEO of Quest PharmaTech since August, 2006; and Director since July, 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 30 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of a number of patents.
Here is a short abstract of what he will be speaking on:
The recent successes of Provenge and Yervay in advanced prostate cancer and melanoma, respectively, have established that immunotherapy has a role in the treatment of human cancer. Recent insights into immune regulation and the effect of combinations create a huge opportunity to explore novel approaches and establish safer and simpler next generation treatments of cancer. Quest PharmaTech provides a platform of proprietary antibodies with a body of clinical experience and a new appreciation of the obstacles and potential of combinatorial immunotherapeutic approaches to cancer.